The Effect of Medication Review in High-risk Emergency Department Patients
Study Details
Study Description
Brief Summary
Adverse drug events are unintended and harmful events related to medication use and a leading cause of emergency department visits, unplanned hospital admissions and deaths. In the emergency department, physicians frequently misdiagnose adverse drug events leading to treatment delays. Our objective is to evaluate the effect of pharmacist-led medication review in high-risk emergency department patients on prolonged hospital stay.
This prospective multi-centre, quasi-randomized study is nested within an existing quality improvement program. Triage nurses flag incoming emergency department patients at high-risk for adverse drug events by applying a clinical decision rule consisting of four variables (co-morbid conditions, antibiotic use within 7 days, medication changes within 28 days, and age). Consecutive eligible high-risk patients are enrolled into the medication review study, and systematically allocated to pharmacist-led medication review or usual care. In the intervention group, medication review pharmacists collect best-possible medication histories, review the patient's medications for appropriateness and adverse drug events, and communicate the results of medication review to patients, caregivers and physicians. In the usual care group, physicians refer patients to onsite pharmacists for medication management questions on an as needed basis. Health outcomes are assessed using anonymized data linkage to administrative health databases. The primary outcome is the percent of days spent in hospital during the first 30 days after the index emergency department visit
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Pharmacist-led medication review Pharmacist-led medication review in the ED |
Other: Pharmacist-led medication review
Medication review is a structured, critical examination of a patient's medications with the objective of reaching agreement with the patient about treatment, optimizing the medications' impact, and minimizing the number of medication-related problems and adverse drug events.
|
| No Intervention: Usual care Usual care includes nurse-led medication reconciliation. |
Outcome Measures
Primary Outcome Measures
- Proportion of days spent in hospital over 30 days [30 days]
The primary outcome will be the proportion of days spent in hospital during the follow up period. This outcome captures all days in hospital that were incurred during the index admission as well as during any readmissions.
Secondary Outcome Measures
- Hospital admission [on the 1 day of medication review]
- Prolonged hospital stay [30 days]
Prolonged hospital stay will be defined as a length of stay that is greater than the median length of stay observed by high-risk patents during the pilot period.
- Unplanned emergency department re-visit [7 days]
- Mortality [30 days]
- Unplanned readmission [30 days]
Eligibility Criteria
Criteria
Inclusion Criteria:
Consecutive high-risk patients, aged 19 years or older, presenting to a participating emergency department when a medication review pharmacist is on duty are eligible for enrolment.
Exclusion Criteria:
We will exclude patients categorized as Canadian Triage Acuity Score (CTAS) 1 as they require immediate resuscitation, those presenting for multisystem trauma (e.g., penetrating trauma), scheduled visits (e.g., for intravenous antibiotics), sexual assaults, pregnancy-related complications, social problems, and those for whom we cannot link data to administrative records (e.g., out-of-province patients).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Lions Gate Hospital | North Vancouver | British Columbia | Canada | |
| 2 | Richmond Hospital | Richmond | British Columbia | Canada | |
| 3 | Vancouver General Hospital | Vancouver | British Columbia | Canada |
Sponsors and Collaborators
- University of British Columbia
Investigators
- Principal Investigator: Corinne M Hohl, MD, MHSc, University of British Columbia
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- H11-01815